These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33064671)

  • 1. SARS-CoV-2-specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19.
    Paschold L; Simnica D; Willscher E; Vehreschild MJ; Dutzmann J; Sedding DG; Schultheiß C; Binder M
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33064671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients.
    Yan Q; He P; Huang X; Luo K; Zhang Y; Yi H; Wang Q; Li F; Hou R; Fan X; Li P; Liu X; Liang H; Deng Y; Chen Z; Chen Y; Mo X; Feng L; Xiong X; Li S; Han J; Qu L; Niu X; Chen L
    Emerg Microbes Infect; 2021 Dec; 10(1):1097-1111. PubMed ID: 33944697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 B cell receptor signatures in at-risk populations.
    Flyak AI
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33216735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals.
    Yoshida S; Ono C; Hayashi H; Fukumoto S; Shiraishi S; Tomono K; Arase H; Matsuura Y; Nakagami H
    Sci Rep; 2021 Mar; 11(1):5934. PubMed ID: 33723294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients.
    Xiang H; Zhao Y; Li X; Liu P; Wang L; Wang M; Tian L; Sun HX; Zhang W; Xu Z; Ye B; Yuan X; Wang P; Zhang N; Gong Y; Bian C; Wang Z; Yu L; Yan J; Meng F; Bai C; Wang X; Liu X; Gao K; Wu L; Liu L; Gu Y; Bi Y; Shi Y; Zhang S; Zhu C; Xu X; Wu G; Gao GF; Yang N; Liu WJ; Yang P
    Hum Immunol; 2022 Feb; 83(2):119-129. PubMed ID: 34785098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients.
    Wang B; Wang L; Kong X; Geng J; Xiao D; Ma C; Jiang XM; Wang PH
    J Med Virol; 2020 Sep; 92(9):1684-1689. PubMed ID: 32343415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent SARS-CoV-2-specific T- and B-cell responses in severe but not mild COVID-19 patients.
    Oja AE; Saris A; Ghandour CA; Kragten NAM; Hogema BM; Nossent EJ; Heunks LMA; Cuvalay S; Slot E; Linty F; Swaneveld FH; Vrielink H; Vidarsson G; Rispens T; van der Schoot E; van Lier RAW; Ten Brinke A; Hombrink P
    Eur J Immunol; 2020 Dec; 50(12):1998-2012. PubMed ID: 33073359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
    Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
    J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.
    Mveang Nzoghe A; Essone PN; Leboueny M; Maloupazoa Siawaya AC; Bongho EC; Mvoundza Ndjindji O; Avome Houechenou RM; Agnandji ST; Djoba Siawaya JF
    Immun Inflamm Dis; 2021 Mar; 9(1):128-133. PubMed ID: 33320447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.
    Shu H; Wang S; Ruan S; Wang Y; Zhang J; Yuan Y; Liu H; Wu Y; Li R; Pan S; Ouyang Y; Yuan S; Zhou P; Shang Y
    Virol Sin; 2020 Dec; 35(6):744-751. PubMed ID: 32720214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration.
    Newell KL; Clemmer DC; Cox JB; Kayode YI; Zoccoli-Rodriguez V; Taylor HE; Endy TP; Wilmore JR; Winslow GM
    PLoS One; 2021; 16(1):e0244855. PubMed ID: 33507994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: Significance of antibodies.
    Assadiasl S; Fatahi Y; Zavvar M; Nicknam MH
    Hum Antibodies; 2020; 28(4):287-297. PubMed ID: 32986664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19.
    Vogelzang EH; Loeff FC; Derksen NIL; Kruithof S; Ooijevaar-de Heer P; van Mierlo G; Linty F; Mok JY; van Esch W; de Bruin S; Vlaar APJ; ; Seppen B; Leeuw M; van Oudheusden AJG; Buiting AGM; Jim KK; Vrielink H; Swaneveld F; Vidarsson G; van der Schoot CE; Wever PC; Li W; van Kuppeveld F; Murk JL; Bosch BJ; Wolbink GJ; Rispens T
    J Immunol; 2020 Dec; 205(12):3491-3499. PubMed ID: 33127820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020.
    Yoshiyama T; Saito Y; Masuda K; Nakanishi Y; Kido Y; Uchimura K; Mitarai S; Suzuki T; Nakagama Y; Kubota H; Satomi M; Uchikoba S; Ohnishi M; Wakita T; Kato S; Kato K
    Emerg Infect Dis; 2021 Feb; 27(2):628-631. PubMed ID: 33496235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing CD8
    Gujar S; Pol JG; Kim Y; Kroemer G
    Oncoimmunology; 2020 Jul; 9(1):1794424. PubMed ID: 32923158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.
    Trinité B; Tarrés-Freixas F; Rodon J; Pradenas E; Urrea V; Marfil S; Rodríguez de la Concepción ML; Ávila-Nieto C; Aguilar-Gurrieri C; Barajas A; Ortiz R; Paredes R; Mateu L; Valencia A; Guallar V; Ruiz L; Grau E; Massanella M; Puig J; Chamorro A; Izquierdo-Useros N; Segalés J; Clotet B; Carrillo J; Vergara-Alert J; Blanco J
    Sci Rep; 2021 Jan; 11(1):2608. PubMed ID: 33510275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates.
    Liu T; Hsiung J; Zhao S; Kost J; Sreedhar D; Hanson CV; Olson K; Keare D; Chang ST; Bliden KP; Gurbel PA; Tantry US; Roche J; Press C; Boggs J; Rodriguez-Soto JP; Montoya JG; Tang M; Dai H
    Nat Biomed Eng; 2020 Dec; 4(12):1188-1196. PubMed ID: 33122853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.